STOCK TITAN
  1. Home
  2. News
  3. NPCE

NeuroPace Inc - NPCE STOCK NEWS

Welcome to our dedicated news page for NeuroPace (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on NeuroPace.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NeuroPace's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NeuroPace's position in the market.

News
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
Rhea-AI Summary
NeuroPace, a medical device company specializing in epilepsy treatment, will release its first-quarter 2024 financial results on May 8, 2024. The management will host a conference call for investors to discuss the results. Interested parties can access the live webcast or participate via telephone. The webcast will be archived for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
conferences earnings
-
News
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
Rhea-AI Summary
NeuroPace, Inc. (NPCE) to present at the Needham 23rd Annual Healthcare Conference. CEO Joel Becker to provide a corporate presentation on April 8. The company focuses on epilepsy treatment and will engage in investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
conferences
-
News
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
Rhea-AI Summary
NeuroPace, Inc. (NPCE) reported a 41% increase in revenue to $18.0 million in Q4 2023 compared to Q4 2022, a 44% increase to $65.4 million in 2023 over 2022. The company provided a revenue guidance of $73-$77 million for 2024. Initiatives like Project CARE and the NAUTILUS study show strategic growth plans. Gross margin increased to 75.2% in Q4 2023. Operating expenses were effectively managed, resulting in a reduced cash burn of $3.4 million in Q4 2023. Full-year 2023 revenue grew 44% to $65.4 million, with a focus on RNS System sales and DIXI Medical products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none
News
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
Rhea-AI Summary
NeuroPace, Inc. (NPCE) to Report Q4 and Full Year 2023 Financial Results on March 5, 2024. The company will host a conference call for investors to discuss the results. Webcast and call details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
conferences earnings
-
News
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates
Rhea-AI Summary
NeuroPace, Inc. (NPCE) expects Q4 2023 revenue between $17.5-18.0 million, with full-year 2023 revenue between $64.9-65.4 million. The company also announced a cash balance of $66.5 million and completed milestones in patient implant, data collaboration, and a pilot program. The NAUTILUS trial for epilepsy treatment is progressing ahead of schedule. The company's CEO expressed satisfaction with 2023 accomplishments and optimism for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.89%
Tags
none
-
News
NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) completes patient enrollment goal in its NAUTILUS pivotal study for the treatment of idiopathic generalized epilepsy (IGE) more than one quarter ahead of schedule. The RNS System could secure the first device-based indication for generalized epilepsy, addressing the treatment gap for the 1.2 million drug refractory epilepsy patients in the United States.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
none
News
NeuroPace to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags
conferences
-
News
NeuroPace to Leverage the Power of its RNS System’s Novel Data Collection, Brain Monitoring and Analysis Capabilities in Groundbreaking Collaboration
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) announced a strategic collaboration with a clinical-stage biotechnology company to leverage RNS System’s unique biomarker monitoring and data analysis capabilities. The collaboration involves tracking responses of implanted RNS System patients enrolled in the biotechnology company’s clinical trial. NeuroPace will receive up to $3.7 million over two years for providing non-exclusive access to its proprietary biomarker monitoring and data analysis capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.21%
Tags
none
-
News
NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting
Rhea-AI Summary
NeuroPace, Inc. (Nasdaq: NPCE) will have a substantial presence at the 77th American Epilepsy Society Annual Meeting, featuring over 50 scientific presentations and posters regarding the RNS System, a therapy option for drug resistant epilepsy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
News
NeuroPace to Present at the Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Summary
NeuroPace, Inc. (NPCE) to present at Piper Sandler 35th Annual Healthcare Conference, with CEO Joel Becker providing a corporate presentation on November 28 at 2:30pm ET. The company will also participate in one-on-one meetings with investors during the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
conferences
Stock NPCE logo
NeuroPace Inc

Nasdaq:NPCE

NPCE Rankings

#3214 Ranked by Market Cap
#119 Ranked by Stock Gains
N/A Ranked by Dividends

NPCE Stock Data

382.65M
10.70M
3.95%
80.9%
0.3%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Mountain View

About NPCE

the rns® system is an award-winning technology developed and manufactured in silicon valley that has been recognized for its innovation. similar to a pacemaker that monitors and responds to heart rhythms, the rns system is the world's first and only medical device that can monitor and respond to brain activity. neuropace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. the company's initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.in addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.